title: Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.
abstract: Active immunotherapy aimed at the stimulation of tumor-specific T cells has established itself within the clinic as a therapeutic option to treat cancer. One strategy is the use of so-called peptides that mimic genuine T-cell epitopes as vaccines to activate tumor-specific T cells. In various clinical trials, different types of vaccines, adjuvants and other immunomodulatory compounds were evaluated in patients with different types of tumors. Here, we review the trials published in the last 3 years focusing on the T-cell response, the effect of immunomodulation and potential relationships with clinical outcomes. Furthermore, we would like to make a case for the development of peptide vaccines aiming to treat non-small-cell lung cancer, the most common cause of cancer mortality.
authors.affiliation: Department of Pulmonology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Talebian Yazdi
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Keene
authors.forename: Pieter S
authors.initials: PS
authors.lastname: Hiemstra
authors.forename: Sjoerd H
authors.initials: SH
authors.lastname: van der Burg
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D002289:Carcinoma, Non-Small-Cell Lung / Q000517:prevention & control* / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology / Q000302:isolation & purification
chemical_list: D019496:Cancer Vaccines; D022223:Vaccines, Subunit